PDS Biotechnology Corp
NASDAQ:PDSB

Watchlist Manager
PDS Biotechnology Corp Logo
PDS Biotechnology Corp
NASDAQ:PDSB
Watchlist
Price: 0.8533 USD 2.41% Market Closed
Market Cap: 44.7m USD

PDSB's latest stock split occurred on Mar 18, 2019

The company executed a 1-for-20 stock split, meaning that for every 20 shares held, investors received 1 new share.

Before the split, PDSB traded at 0.504 per share. Afterward, the share price was about 9.4.

The adjusted shares began trading on Mar 18, 2019. This was the only stock split in PDSB's history.

Last Splits:
Mar 18, 2019
1-for-20
Pre-Split Price
10.08 0.504
Post-Split Price
9.4
Before
After
Last Splits:
Mar 18, 2019
1-for-20

PDS Biotechnology Corp
Stock Splits History

PDSB Stock Splits Timeline
Mar 18, 2019
Mar 18, 2019
Split 1-for-20
/0.05
Pre-Split Price
10.08 0.504
Post-Split Price
9.4
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Jan 20, 2026
Linius Technologies Ltd
OTC:LNNTF
1-for-100
/100
0.0001 0.0001 USD N/A
Jan 20, 2026
Lotus Resources Ltd
OTC:LTSRF
1-for-11
/11
0.14 0.14 USD N/A
Jan 15, 2026
Amcor PLC
NYSE:AMCR
1-for-5
/5
8.46 8.46 USD N/A
Jan 8, 2026
Sumitomo Realty & Development Co Ltd
OTC:SURYY
2-for-1
x2
25.635 25.635 USD N/A
Dec 30, 2025
Adicet Bio Inc
NASDAQ:ACET
1-for-16
/16
0.4921 0.4921 USD 7.93 7.93 USD
Load More

PDS Biotechnology Corp
Glance View

Market Cap
40.7m USD
Industry
Biotechnology

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. The company is headquartered in Florham Park, New Jersey and currently employs 22 full-time employees. The company went IPO on 2015-10-01. The firm is engaged in the developing a pipeline of molecularly targeted immunotherapies. The firm owns the T-cell activating platforms designed to train the immune system to attack and destroy disease; Versamune, for treatments in oncology and Infectimune, for treatments in infectious disease. Infectimune is also designed to promote the induction of disease-specific neutralizing antibodies. Its immuno-oncology product candidates are of potential interest for use as a component of combination product candidates to provide treatments across a range of advanced and/or refractory cancers. The company develops targeted product candidates to treat several cancers, including Human Papillomavirus (HPV) associated cancers, melanoma, colorectal, lung, breast and prostate cancers. Its infectious disease candidates are of potential interest as vaccines to prevent COVID-19 and universal influenza.

PDSB Intrinsic Value
Not Available
Back to Top